#United States #Boston #Biopharma #IDBS #AI Adoption

IDBS to Host the i3 2026 Forum in Boston

IDBS, a part of Danaher, has announced the i3 2026 forum, a premier event set to take place on May 18, 2026, in Boston, just a day before the Bio-IT World Conference. The forum aims to gather leaders from the BioPharma sector to navigate the complexities of integrating artificial intelligence (AI), automation, and advanced analytics into their workflows.

As BioPharma organizations rapidly embrace these technologies, they often face hurdles such as fragmented experiment data, outdated legacy systems, and increasing regulatory demands. The pressure is on research, development, IT, and digital leaders to modernize their data management processes while ensuring compliance and maintaining the pace of scientific discovery.

Pietro Forgione, General Manager at IDBS, stated, “Our customers are addressing these challenges directly by reimagining how they capture and contextualize scientific data. By integrating IDBS solutions into their digital infrastructures, they build more reliable and scalable frameworks for decision-making.” The i3 2026 forum serves as a platform for sharing insights on what strategies are working, lessons learned, and future directions for the industry, all while considering both GxP and non-GxP environments.

Following the success of last year's i3 2025 event in Woking, the 2026 forum moves to AWS BOS17, located in Boston’s vibrant Seaport district. Attendees can look forward to a day filled with dynamic presentations from customers who have successfully integrated IDBS solutions into their operational frameworks. The agenda will also include strategic insights from IDBS leadership and in-depth technical sessions focusing on platform capabilities.

Key Themes of the Forum:

• - Customer Spotlights: Learn from BioPharma organizations about their real-world experiences in adopting IDBS solutions.
• - Strategic Insights: Gain perspective on IDBS’s platform vision and market trends that empower connected, data-driven laboratories.
• - Technical Deep Dives: Participate in technical sessions discussing cloud-native architectures, data capture, and automation techniques.
• - GxP in Practice: Explore approaches for maintaining compliance while enhancing decision-making speed and confidence.

This forum reflects Danaher’s commitment to fostering connections between data, workflows, and teams throughout the scientific lifecycle. By facilitating better management of these elements, Danaher aims to support its clients in accelerating the transition from discovery to market delivery, enhancing both speed and reliability.

Registration for the i3 2026 forum is currently open to IDBS customers and invited partners. To register, attendees can visit idbs.com/i3.

About IDBS

IDBS, the cloud software pioneer under Danaher, focuses on empowering biopharma organizations to harness the potential of AI and machine learning (ML) to enhance patient care. Serving as a partner to 80% of the top 20 global biopharma companies, IDBS offers comprehensive cloud solutions tailored to meet industry-specific needs.

With over 35 years of expertise in scientific informatics, IDBS assists organizations in orchestrating processes, managing data, and deriving insights throughout the product lifecycle, from research and development through to manufacturing. The company’s flagship IDBS E-WorkBook software exemplifies their innovative spirit, expanding into robust cloud platforms like IDBS Polar to elevate the decision-making capabilities of scientists across both regulated and unregulated environments.

About Danaher

Danaher is a global leader in life sciences and diagnostics innovation, dedicated to enhancing human health through advanced science and technology. The company collaborates closely with clients to tackle their most pressing scientific challenges, enabling faster and more effective solutions for patients. Supported by the Danaher Business System, their innovative capabilities lead the way in driving significant improvements in healthcare quality and outcomes. For more information, visit www.danaher.com.